#USA #New Orleans #Kodiak Sciences #KSI-101 #Zenkuda

Kodiak Sciences to Present Clinical Data Across All Three Late-Stage Programs at AAO 2026

Kodiak Sciences Inc. (Nasdaq: KOD), a pioneering biotechnology firm concentrating on retina health, is set to present critical clinical data on its late-stage drug programs at the American Academy of Ophthalmology Annual Meeting (AAO 2026) in New Orleans. The event, which will unfold from October 9 to October 12, 2026, marks a notable opportunity for the company to showcase its commitment to advancing therapeutic solutions for retinal diseases.

One of the primary highlights of Kodiak’s presentation will be the results of the Phase 3 DAYBREAK study, which examines the efficacy of Zenkuda (tarcocimab tedromer) and tabirafusp-ted (KSI-501) in treating patients with wet age-related macular degeneration (wet AMD). This presentation, scheduled for October 9, will be led by Dr. Charles Wykoff, a renowned ophthalmologist and chairman of research at Retina Consultants of Texas.

The DAYBREAK study has produced results that indicate both Zenkuda and tabirafusp-ted provide non-inferior vision gains when compared to the existing treatment standard, aflibercept, at the one-year mark. This finding is not only promising for patients suffering from wet AMD but also signifies a potential shift in treatment protocols within clinical practices.

In addition to the DAYBREAK results, Kodiak will present the Phase 3 GLOW2 data on Zenkuda's effectiveness for diabetic retinopathy, which further emphasizes the versatility of this promising therapeutic agent. This session, taking place on October 10, will be presented by Dr. Margaret Chang from the Retina Consultants Medical Group, providing insights into Zenkuda’s broader applicability in retinal pathologies.

Moreover, the company aims to discuss findings from the Phase 1b APEX study, which investigates the use of KSI-101 in macular edema secondary to inflammation. Dr. Edmund Tsui of UCLA will present these results during the Uveitis Subspecialty Day, underscoring Kodiak's commitment to developing innovative solutions for various retinal conditions.

Overall, Kodiak Sciences is focused on delivering transformative therapies that can address some of the leading causes of vision loss globally. The company’s pipeline, particularly its lead candidates Zenkuda and KSI-501, is geared toward targeting the substantial market of anti-VEGF therapies, valued at approximately $15 billion across retinal vascular diseases.

As Kodiak prepares for this pivotal congress, it looks towards significant advancements not only for its treatment protocols but for the hundreds of thousands of patients in need of effective therapeutic options for chronic retinal conditions. The upcoming presentations at AAO 2026 will undoubtedly bolster Kodiak’s position within the retinal therapeutics landscape and pave the way for future innovations in eye care.

This year marks a crucial moment for Kodiak Sciences, as it continues to engage with the scientific community, clinicians, and patients. The upcoming AAO 2026 presentations stand as a testament to the company's dedication to improving outcomes for individuals suffering from debilitating vision disorders. As the meeting unfolds, stakeholders eagerly await to see how Kodiak's innovations will influence the future of retinal health treatments.